Theragenics Corp (TGX-N) Stock Predictions - Stockchase
WATCH LIST
13
Theragenics Corp (TGX-N)

ON STOCKCHASE SINCE Jul 2004

Cancer treatment

Merged with Juniper (Oct 2013)

biotechnology/pharmaceutical

Theragenics Corp

TGX-N

2 watching          
Join the Discussion

Theragenics Corp (TGX-N) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about TGX-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Theragenics Corp(TGX-N) 

December 6, 2011

(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.660
Owned Owned
No

PAST TOP PICK
Theragenics Corp(TGX-N) 

November 3, 2011

(A Top Pick Nov 11/10. Up 28.57%.)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Nov 11/10. Up 28.57%.)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.600
Owned Owned
Yes

PAST TOP PICK
Theragenics Corp(TGX-N) 

October 4, 2011

(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.250
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

November 11, 2010

Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$1.300
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

December 24, 2007

Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$3.710
Owned Owned
Yes

WEAK BUY
Theragenics Corp(TGX-N) 

October 6, 2006

Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$3.070
Owned Owned
Yes

PAST TOP PICK
Theragenics Corp(TGX-N) 

January 30, 2006

(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$3.480
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

September 6, 2005

In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ben Stadelmann

Vice Presi, Contra the Heard...

Price Price
$3.150
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

January 12, 2005

They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ben Stadelmann

Vice Presi, Contra the Heard...

Price Price
$3.970
Owned Owned
Yes

PAST TOP PICK
Theragenics Corp(TGX-N) 

November 9, 2004

(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$3.900
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

September 16, 2004

A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ben Stadelmann

Vice Presi, Contra the Heard...

Price Price
$3.740
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

July 21, 2004

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$4.360
Owned Owned
Yes

TOP PICK
Theragenics Corp(TGX-N) 

July 16, 2004

Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Benj Gallander

President, Contra the Heard Inv...

Price Price
$4.370
Owned Owned
Yes

Showing 1 to 13 of 13 entries
Successfully Saved Company
Successfully Saved Company